Table 2.
Association of NNRTI resistance mutations with rilpivirine cross-resistance.
| Mutationa | Resistant (≥2.5-fold) |
Susceptibleb (<2.5-fold) |
|||
|---|---|---|---|---|---|
| n = 69 | n = 43 | Odds ratio | p | q | |
| NVP- and/or EFV-associated resistance mutations | |||||
| K103N | 44 (64%) | 11 (26%) | 5.12 | <0.001 | 0.046 |
| V106M | 22 (32%) | 22 (51%) | 0.44 | 0.049 | 0.84 |
| V108I | 13 (19%) | 0 (0%) | Inf | 0.002 | 0.167 |
| P225H | 11 (16%) | 2 (5%) | 3.88 | 0.199 | 1 |
| RPV-associated resistance mutations | |||||
| K101E | 8 (12%) | 2 (5%) | 2.69 | 0.312 | 1 |
| E138A | 7 (6%) | 2 (5%) | 2.31 | 0.478 | 1 |
| E138K | 3 (4%) | 0 (0%) | Inf | 0.284 | 1 |
| V179I | 8 (12%) | 1 (2%) | 5.51 | 0.150 | 1 |
| V179L | 0 (0%) | 0 (0%) | na | na | na |
| H221Y | 6 (9%) | 2 (5%) | 1.95 | 0.708 | 1 |
| F227C | 0 (0%) | 0 (0%) | na | na | na |
| NVP-, EFV- and RPV-associated resistance mutations | |||||
| L100I | 13 (19%) | 0 (0%) | Inf | 0.002 | 0.167 |
| Y181C | 15 (22%) | 1 (2%) | 11.67 | 0.004 | 0.276 |
| Y188L | 6 (9%) | 0 (0%) | Inf | 0.080 | 0.943 |
| G190A | 14 (20%) | 12 (28%) | 0.66 | 0.367 | 1 |
| M230L | 10 (14%) | 1 (2%) | 7.12 | 0.049 | 0.840 |
a
Mutations listed are considered major NVP-, EFV- and/or RPV-associated as reported by Stanford HIV Drug Resistance Database and IAS 2017.19,26
b
Sample size includes N = 12 “control” samples derived from ARV treatment naïve individuals from South Africa.Statistical significance is indicated with bold-faced text.